Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13507MR)

This product GTTS-WQ13507MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13507MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9012MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ4398MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ73MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ14477MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ5666MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ2211MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ3019MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ13156MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW